Phase and cell cycle specificity of pyrazofurin action

Cancer Research

Volumn 40, Issue , 1980, Pages 2869-2875

  Olah, Edith ^a   Lui, May S ^a   Tzeng, Diana Y ^a   Weber, George ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84969039921     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Brockman, R.W., Shaddix, S.C., and Rose, L.M. Biochemical aspects of chemotherapy of mouse colon carcinoma. Cancer (Phila.), 40: 2681–2691, 1977.
2. Cadman, E.C. Dix, D.E., and Handschumacher, R.E. Clinical, biological, and biochemical effects of Pyrazofurin. Cancer Res., 38: 682–688, 1978.
3. Dix, D.E., Lehman, C.P., Jakubowski, A., Moyer, J.D., and Handschu-macher, R.E. Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. Cancer Res., 39: 4485–4490, 1979.
4. Ferdinandus, J.A., and Weber, G. Effect of 5-diazouracil on the synthetic and catabolic utilization of thymine in rat liver. Proc. Soc. Exp. Biol. Med., 139: 592–596, 1972.
5. Gralla, R.J., Currie. V.E., Wittes. R.E. Golbey, R.B., and Young, C.W. Phase II evaluation of Pyrazofurin in patients with carcinoma of the lung. Cancer Treat. Rep., 62: 451–452, 1978.
6. Gutowski, G.E., Sweeney, M.J., DeLong, D.C., Hamill, R.L., Gerzon, K., and Dyke, R.W. Biochemistry and biological effects of Pyrazofurins (pyra-zomycins): Initial clinical trial. Ann. N. Y. Acad. Sci., 255; 544–551, 1975.
7. Jackson, R.C., Boritzki, T.J., Morris, H.P., and Weber, G. Purine and pyrimidine ribonucleotide contents of rat liver and hepatoma 3924A and the effect of ischemia. Life Sci., 19: 1531–1536, 1976.
8. Jackson, R.C., Boritzki, T.J., and Weber, G. Thymidine rescue from methotrexate or 5-ftuorodeoxyuridine: Enhancement by 5-diazouracil. In: W. Siegenthaler and R. Luethy (eds), Current Chemotherapy, Proceedings of the Tenth International Society of Chemotherapy, pp. 1264–1266. Washington, D. C.: American Society for Microbiology, 1978.
9. Looney, W.B., Mayo, A.A. Janners, M.Y., Mellon, J.G. Allen. P., Salak, D.and Morris, H.P. Cell proliferation and tumor growth in hepatoma 3924A. Cancer Res., 31:821–825,1971.
10. Lui, M.S., Jackson, R.C., and Weber, G. Enzyme pattern-directed chemotherapy: Effects of antipyrimidine combinations on the ribonucleotide content of hepatomas. Biochem. Pharmacol., 28: 1189–1195, 1979.
11. Ohnuma, T., Roboz, J., Shapiro. M.L., and Holland. J.F. Pharmacological and biochemical effects of Pyrazofurin in humans. Cancer Res. 37. 2043–2049.1977.
12. Otah, E., Palyi, I., and Sugar, J. Effects of cytostatics on proliferating and stationary cultures of mammalian cells. Eur. J. Cancer, 14:895–900,1978.
13. Olah, E., and Weber. G. Giemsa-banding karyotype of rat hepatomas of different growth rates. Cancer Res. 39:1708–1717, 1979.
14. Ptagemann, P.G.W., and Behrens, M. Inhibition of de novo pyrimidine nucleotide and DNA synthesis and growth of cultured Novikoff rat hepatoma cells and other cell lines by Pyrazofurin (NSC 143095). Cancer Res. 36: 3807–3812,1976.
15. Quastler, H., and Sherman, F.G. Cell population kinetics in the intestinal epithelium of the mouse. Exp. Cell Res., 17: 420–438, 1959.
16. Roboz, J., and Ohnuma, T. Mass spectrometric identification and quantification of compounds involved in the metabolism of Pyrazofurin. In: A. Frigerio and E. L. Ghisalberti (eds.). Mass Spectrometry in Drug Metabolism pp. 151–165. New York: Plenum Publishing Corp., 1977.
17. Streightoff, F.J., Nelson, J.D., Cline, J.C. Gerzon, K., Hoehn M. Williams R.H., Gorman, M., and Delong, D.C. Antiviral activity of pyrazomycin. In: Proceedings of the Ninth Conference on Antimicrobial Agents and Chemotherapy. p. 8. Washington, D. C.: American Society for Microbiology 1969.
18. Sweeney, M.J. Davis F.A., Gutowski, G.E., Hamill, R.L., Hoffman D.H. and Poore. G.A. Experimental antitumor activity of pyrazomycin. Cancer Res., 33: 2619–2623, 1973.
19. Sweeney, M.J., Parton, J.W., and Hoffman, D.H. Biosynthesis of uridine 5'-monophosphate in rat liver and Morris hepatomas. Adv. Enzyme Regul., 12: 385–396, 1974.
20. Terasima, T., and Tolmach, L.J. Changes in X-ray sensitivity of HeLa cells during the division cycle. Nature (Lond.), 190: 1210–1211. 1961.
21. Valeriote, F., and Van Putten, L. Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res., 35: 2619–2630, 1975.
22. Weber. G. Enzymology of cancer cells. Part 1. N. Engl. J. Med., 296: 486–493, 1977.
23. Weber, G. Enzymology of cancer cells. Part 2. N. Engl. J. Med., 296: 541–551, 1977.
24. Weber, G. Shiotani, T., Kizaki, H. Tzeng, D., Williams, J.C. and Gladstone, N. Biochemical strategy of the genome as expressed in regulation of pyrimidine metabolism. Adv. Enzyme Regul., 16: 3–19, 1978.
25. Weber, G., Stubbs, M., and Morris, H.P. Metabolism of hepatomas of different growth rates in situ and during ischemia. Cancer Res., 31: 2177–2183, 1971.
26. Worzalla, J.F., and Sweeney, M.J. Pyrazofurin inhibits de novo purine biosynthesis in rats. Proc. Am. Assoc. Cancer Res., 19: 56, 1978.